A Phase IIIB Multi-Center, Open-Label, Prospective, Repeated Dose, Multi-Day Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients

Trial Profile

A Phase IIIB Multi-Center, Open-Label, Prospective, Repeated Dose, Multi-Day Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2017

At a glance

  • Drugs Paracetamol (Primary)
  • Indications Acute pain; Fever
  • Focus Adverse reactions; Registrational
  • Sponsors Cadence Pharmaceuticals
  • Most Recent Events

    • 02 Nov 2010 According to a Cadence Pharmaceuticals media release, the US FDA has approved OFIRMEV (IV parcetamol) for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.
    • 19 Jan 2009 Status changed from active, no longer recruiting to completed.
    • 17 Dec 2008 Results are expected in the first quarter of 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top